Navigate Compliance Waters

Widler & Schiemann AG can provide you with innovative, creative and cost effective answers to your questions and needs in the areas of Clinical Quality Management. With our vast experience and extensive network in the industry and the regulators we are uniquely positioned to identify and provide the best solutions for you.

Our Services

Download as PDF
  • 01 June 2021
  • 41
COVID-19: Master Protocols Evaluating Drugs and Biological Products for Treatment or Prevention
On 17 May 2021 the FDA issued this final guidance for industry.
Read more online Read
  • 01 June 2021
  • 35
Manufacturing, Supply Chain, and Drug and Biological Product Inspections During COVID-19 Public Health Emergency: Questions and Answers
On 17 May 2021 the FDA issued this Q&A guidance for industry.
Read more online Read
  • 01 June 2021
  • 41
Chemotherapy-Induced Nausea and Vomiting: Developing Drugs for Prevention
On 19 May 2021 the FDA published this draft guidance for industry. Comments should be submitted by 19 July 2021.
Read more online Read
  • 01 June 2021
  • 46
Testing and Labeling Medical Devices for Safety in the Magnetic Resonance (MR) Environment
On 19 May 2021 the FDA published this final guidance for industry and FDA staff.
Read more online Read
  • 01 June 2021
  • 48
Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs
On 19 May 2021 the FDA published the draft guidance on questions regarding the Statement of Investigator Form 1572.
Read more online Read
  • 01 June 2021
  • 49
ICH Q12: Implementation Considerations for FDA-Regulated Products
On 19 May 2021 the FDA published this draft guidance on the International Council for Harmonization (ICH) Q12 for industry.
Read more online Read
  • 01 June 2021
  • 58
Conveying Medical Device Materials Information to Patients and Clinicians: Considerations for a Framework
On 20 May 2021 the FDA published the discussion paper on conveying information about medical device materials.
Read more online Read
  • 01 June 2021
  • 32
Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products
On 20 May 2021 the FDA published this draft guidance for industry.
Read more online Read
  • 01 June 2021
  • 27
Bispecific Antibody Development Programs
On 24 May 2021 the FDA published this final guidance for industry.
Read more online Read
  • 01 June 2021
  • 17
Notify the MHRA about a Clinical Investigation for a Medical Device
On 25 May 2021 the MHRA updated the guidance on notifying the MHRA of a proposed clinical investigation for a medical device.
Read more online Read
  • 01 June 2021
  • 23
EU Medical Device Regulation Comes into Application
On 26 May 2021 the EMA announced that the Regulation (EU) 2017/745 on medical devices became applicable in the EU.
Read more online Read
  • 17 May 2021
  • 82
Guidance Notes on the Management of Safety Information and Product Complaints Digital Activities
On 27 April 2021 the Association of the British Pharmaceutical Industry (ABPI) published the informal guidance notes.
Read the pdf Read
  • 17 May 2021
  • 72
The Danish Medicines Agency’s Guidance on the Implementation of Decentralised Elements in Clinical Trials with Medicinal Products
On 4 May 2021 the Danish Medicines Agency published the guidance on decentralised clinical trials.
Read more online Read
  • 17 May 2021
  • 45
FDA Outlines Inspection and Assessment Activities During Pandemic, Roadmap for Future State of Operations
On 5 May 2021 the FDA published its Resiliency Roadmap for FDA Inspectional Oversight.
Read more online Read
  • 17 May 2021
  • 48
MHRA Guidance on the Licensing of Biosimilar Products
On 6 May 2021 the UK MHRA published the guidance on the licensing of biosimilar products.
Read more online Read
  • 17 May 2021
  • 55
Is Your eSystem Actually an eCRF (electronic Case Report Form)?
On 11 May 2021 the MHRA Inspectorate published this blog.
Read more online Read
  • 17 May 2021
  • 64
Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management
On 11 May 2021 the FDA published this final guidance for industry.
Read more online Read
  • 17 May 2021
  • 79
Operational Application Programming Interface: Downloading Content for Analysis
On 11 May 2021 ClinicalTrials.gov announced the availability of operational API.
Read
  • 17 May 2021
  • 56
Study Coordinator Charged in Scheme to Falsify Clinical Trial Data
On 11 May 2021 a US Department of Justice federal grand jury returned an indictment charging conspiracy to falsify clinical trial data.
Read more online Read
  • 04 May 2021
  • 90
Draft Principles of ICH E6 Good Clinical Practice (GCP) now Available
On 19 April 2021 the ICH announced the availability of the draft principles of ICH E6 GCP.
Read the pdf Read
  • 04 May 2021
  • 80
CDISC CDASH SAE Supplement v2.0 Released
On 21 April 2021 the CDISC announced the release of the CDASH SAE Supplement version 2.0.
Read more online Read
  • 04 May 2021
  • 82
Request for Proposals for Auditors to Support Audits of MedDRA MSSO Operations
On 21 April 2021 the ICH launched a request for proposal for auditors in support of MedDRA MSSO audits.
Read more online Read
  • 04 May 2021
  • 140
Clinical Trials Information System Reaches Major Milestone towards Go-Live and Application of the Clinical Trial Regulation
On 21 April 2021 the EMA announced that the CTIS is on track to go live with the application of Clinical Trial Regulation.
Read more online Read
  • 04 May 2021
  • 115
Questions and Answers on the Principles of GMP for the Manufacturing of Starting Materials of Biological Origin Used to Transfer Genetic Material for the Manufacturing of ATMPs
On 23 April 2021 the EMA announced the availability of the updated Q&A guidance on GMP.
Read the pdf Read
  • 04 May 2021
  • 199
The ICH Q3C(R8) Guideline Reaches Step 4 of the ICH Process
On 23 April 2021 the ICH announced the status of the maintenance process for the ICHQ3C(R8) guideline.
Read the pdf Read
  • 04 May 2021
  • 97
Nonclinical Testing of Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases
On 26 April 2021 the FDA published draft guidance for sponsor-investigators.
Read more online Read
  • 04 May 2021
  • 274
Public Web Conference Organised by the ICH E6(R3) EWG
On 26 April 2021 the ICH announced a free public web conference held by the ICH E6(R3) GCP EWG on 18-19 May 2021.
Read more online Read
  • 04 May 2021
  • 94
A New Collaboration between SNOMED International and ICH Promotes Seamless Data Exchange in Support of Public Health
On 29 April 2021 the ICH announced a new collaboration between SNOMED International and ICH.
Read more online Read
  • 19 April 2021
  • 130
Clinical Trials Guidance on Notification of Serious Breach
On 1 March 2021 Singapore’s Health Sciences Authority (HSA) published the clinical trials guidance on notification of serious breach.
Read the pdf Read
  • 19 April 2021
  • 113
Development of Abbreviated New Drug Applications (ANDAs) During the COVID-19 Pandemic – Questions and Answers
On 5 April 2021 the FDA issued the final Q&A guidance on ANDAs development during COVID-19.
Read more online Read
  • 19 April 2021
  • 182
Risk Management Information Day 2021
On 9 April 2021 the EMA announced a virtual event about risk management information will be held on 15 June 2021.
Read more online Read
  • 19 April 2021
  • 121
Overview of Comments Received on 'ICH Reflection Paper on Proposed ICH Guideline Work to Advance Patient Focused Drug Development’
On 14 April 2021 the EMA announced the availability of the overview of comments.
Read the pdf Read
  • 19 April 2021
  • 138
Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities During the COVID-19 Public Health Emergency — Guidance for Industry
On 14 April 2021 the FDA issued the final guidance on remote evaluations of drug manufacturing and bioresearch monitoring facilities during COVID-19.
Read more online Read
  • 19 April 2021
  • 271
Updated IRIS Guide to Registration
On 15 April 2021 the EMA announced the availability of the updated IRIS guide on preliminary requirements for all IRIS submissions, including substance and research product identifier registration (version 2.6).
Read the pdf Read
  • 01 April 2021
  • 349
MHRA Updated Guidance on Managing Clinical Trials During Coronavirus (COVID-19)
On 16 March 2021 the UK MHRA updated the guidance on managing clinical trials during COVID-19.
Read more online Read
  • 01 April 2021
  • 336
EMA Updated the Pharmacovigilance System Manual
On 16 March 2021 the EMA updated the pharmacovigilance system manual version 1.3.
Read the pdf Read
  • 01 April 2021
  • 410
EMA Updated the Clinical Trials Information System’s Training Programme
On 16 March 2021 the EMA announced the updates of the clinical trials information system’s training programme.
Read more online Read
  • 01 April 2021
  • 326
Biocompatibility Assessment Resource Center
On 18 March 2021 the FDA launched a biocompatibility assessment resource center for medical devices.
Read more online Read
  • 01 April 2021
  • 355
FDA’s Ongoing Use of Inspectional Tools for Ensuring Access to Safe, Quality Food and Medical Products During the COVID-19 Pandemic
On 18 March 2021 the FDA published insights from its leadership and experts into the FDA’s approach to foreign and domestic inspections.
Read more online Read
  • 01 April 2021
  • 376
Guidance for Industry on MHRA’s Expectations for Return to UK On-site Inspections
On 19 March 2021 the guidance was updated on the MHRA UK risk-based GxP inspection programme.
Read more online Read
  • 01 April 2021
  • 350
Inclusion/Exclusion Criteria for the “Important Medical Events” List
On 24 March 2021 the EMA announced the availability of the updated guidance related to the current version of MedDRA.
Read the pdf Read
  • 01 April 2021
  • 261
Inspectors Grounded – A Year of Innovation
On 26 March 2021 the MHRA inspectorate shared the past year’s inspection experience and the future of innovative inspections.
Read more online Read
  • 01 April 2021
  • 175
Generic Drugs Forum 2021: Lifecycle of a Generic Drug
On 30 March 2021 the FDA announced the Generic Drugs Forum webinar scheduled for 28-29 April 2021.
Read more online Read
  • 01 April 2021
  • 155
MHRA Guidance on Responding to a GLP & GCP Laboratories Inspection Report
On 30 March 2021 the UK MHRA published the guidance for industry on preparing responses to GLP and GCP inspection reports.
Read more online Read
  • 26 March 2021
  • 44
WS Presenting at Swiss Chinese Chamber of Commerce on 30 March 2021
Michael Zang, WSQMS Regulatory Affairs /Global Life Science Consultant, will be presenting at the Swiss Chinese Chamber of Commerce (SCCC) on March 30 2021.

Read more online

  • 16 March 2021
  • 246
Notify the MHRA about a Clinical Investigation for a Medical Device
On 3 March 2021 the MHRA updated the guidance on how to notify the MHRA of a clinical investigation for a medical device.
Read more online Read
  • 16 March 2021
  • 293
COVID-19 Container Closure System and Component Changes: Glass Vials and Stoppers
On 4 March 2021 the FDA published the final guidance for industry.
Read more online Read
  • 16 March 2021
  • 225
Pilot project ‘Market Launch Intentions of Centrally Authorized Products’
On 5 March 2021 the EMA published the guidance on the practical questions and answers about the pilot project.
Read the pdf Read
  • 16 March 2021
  • 259
Workshop on the General Data Protection Regulation (GDPR) and Secondary Use of Data for Medicines and Public Health Purposes
On 5 March 2021 the EMA published the presentation materials from the workshop held on 29 September 2020.
Read more online Read
  • 16 March 2021
  • 259
Questions and Answers to Stakeholders on the Implementation of the Protocol on Ireland/Northern Ireland
On 5 March 2021 the EMA issued additional practical Q&A guidance on the applicable rules in Northern Ireland after the transition period with respect to EMA activities and medicinal products for human and veterinary use within the framework of the centralized procedure.
Read the pdf Read
  • 16 March 2021
  • 349
Register Medical Devices to Place on the Market
On 12 March 2021 the MHRA updated the guidance on how to register medical devices with the MHRA for the markets in Great Britain and Northern Ireland.
Read more online Read
  • 16 March 2021
  • 246
EMA Updated Clinical Trials Information System Development
On 12 March 2021 the EMA announced updated information on the clinical trials information system (CTIS).
Read more online Read
  • 16 March 2021
  • 188
Labelling Flexibilities for COVID-19 Therapeutics
On 12 March 2021 the EMA announced the availability of guidance on labelling flexibilities for COVID-19 treatments.
Read the pdf Read
  • 03 March 2021
  • 215
EMA Updated Q&A: Good Clinical Practice
On 16 February 2021 the EMA updated GCP Q&A by adding a new Q&A (#15) to the GCP Matters section.
Read more online Read
  • 03 March 2021
  • 319
Audit Checklist – Interpretation Guide
On 16 February 2021 the EMA published the first interpretation guide to support the common audit checklist, in cooperation with the members of the joint audit programme.
Read the pdf Read
  • 03 March 2021
  • 230
MHRA Updated Guidance on Managing Clinical Trials during COVID-19
On 17 February 2021 the MHRA updated the guidance by adding a section on the management of COVID-19 vaccine deployment for ongoing non-COVID-19 clinical trials.
Read more online Read
  • 03 March 2021
  • 190
Policy for Evaluating Impact of Viral Mutations on COVID-19 Tests
On 22 February 2021 the FDA issued initial guidance for test developers and FDA staff.
Read more online Read
  • 03 March 2021
  • 193
Emergency Use Authorization for Vaccines to Prevent COVID-19
On 22 February 2021 the FDA issued additional guidance for industry.
Read more online Read
  • 03 March 2021
  • 185
Product Management Services (PMS) – Implementation of International Organization for Standardization (ISO) Standards for the Identification of Medicinal Products (IDMP) in Europe
On 22 February 2021 the EMA published the new regulatory and procedural guideline on product management services: Chapter 8 – Practical examples.
Read the pdf Read
  • 03 March 2021
  • 3330
Product Management Service (PMS) – Implementation of International Organization for Standardization (ISO) Standards for the Identification of Medicinal Products (IDMP) in Europe: Chapter 3
On 22 February 2021 the EMA published the new regulatory and procedural guideline on product management service: Chapter 3 – Process for the electronic submission of medicinal products information.
Read the pdf Read
  • 03 March 2021
  • 259
Clinical Trials Regulation (EU) No 536/2014: Questions & Answers
On 24 February 2021 the European Commission released the draft Q&A on EU clinical trials regulation No 536/2014, version 3.
Read the pdf Read
  • 03 March 2021
  • 209
MHRA Pharmacovigilance Inspection Metrics: April 2019 to March 2020
On 26 February 2021 the MHRA GPvP inspectorate published the latest inspection metrics for the period from April 2019 to March 2020.
Read the pdf Read
  • 17 February 2021
  • 6097
Chinese NMPA Released the National Medical Products Newsletter
In January 2021 the Chinese NMPA published 2021 Volume I of the National Medical Products Newsletter.
Read the pdf Read
  • 17 February 2021
  • 277
Draft Toolbox Guidance on Scientific Elements and Regulatory Tools to Support Quality Data Packages for PRIME Marketing Authorization Applications
On 2 February 2021 the EMA published the draft toolbox guidance. Comments should be submitted by 31 July 2021.
Read the pdf Read
  • 17 February 2021
  • 7150
EMA Guideline on Good Pharmacovigilance Practices (GVP) Module XVI Addendum II
On 3 February 2021 the EMA published the draft guideline on GVP Module XVI Addendum II – Methods for Effectiveness Evaluation. Comments should be submitted by 28 April 2021.
Read the pdf Read
  • 17 February 2021
  • 1124
EMA Guideline on Good Pharmacovigilance Practices (GVP) Module XVI
On 3 February 2021 the EMA published the draft guideline on GVP Module XVI – Risk Minimization Measures: Selection of Tools and Effectiveness Indicators (Rev 3). Comments should be submitted by 28 April 2021.
Read the pdf Read
  • 17 February 2021
  • 288
Guidance on the Management of Clinical Trials During the Covid-19 (Coronavirus) Pandemic
On 4 February 2021 the EMA published guidance version 4 with the key changes of remote source data verification.
Read the pdf Read
  • 17 February 2021
  • 6551
Reference Safety Information (RSI) for Clinical Trials – Part III
On 5 February 2021 the MHRA GCP inspectorate published the RSI blog posts Part III.
Read more online Read
  • 17 February 2021
  • 275
EMA Post-authorization Procedural Advice for Users of the Centralized Procedure
On 8 February 2021 the EMA published the post-authorization guidance.
Read the pdf Read
  • 17 February 2021
  • 260
Investigational COVID-19 Convalescent Plasma
On 11 February 2021 the FDA published revised guidance for industry.
Read more online Read
  • 17 February 2021
  • 258
MHRA Guidance on Pharmacovigilance Requirements for UK Authorized Products from 1 January 2021
On 12 February 2021 the guidance was published on the MHRA inspectorate blog.
Read more online Read
  • 17 February 2021
  • 256
GCP Inspections Metrics Report
On 12 February 2021 the MHRA GCP Inspectorate issued the GCP inspections metrics report covering 1 April 2018 to 31 March 2019.
Read the pdf Read
  • 02 February 2021
  • 268
FDA Released Artificial Intelligence/Machine Learning Action Plan
On 12 January 2021 the FDA released the agency’s first artificial intelligence/machine learning (AI/ML)-based software as a medical device (SaMD) action plan.
Read more online Read
  • 02 February 2021
  • 284
Guidelines 01/2021on Examples Regarding Data Breach Notification
On 18 January 2021 the European Data Protection Board announced the notification for public consultation. Comments should be sent by 2 March 2021.
Read the pdf Read
  • 02 February 2021
  • 32884
Manufacturing Considerations for Licensed and Investigational Cellular and Gene Therapy Products During COVID-19 Public Health Emergency
On 19 January 2021 the FDA published the final guidance for industry.
Read more online Read
  • 02 February 2021
  • 317
Commission Notice – Application of the Union’s Pharmaceutical Acquis in Markets Historically Dependent on Medicines Supply from or through Great Britain after the End of the Transition Period
On 25 January 2021 the EMA published the European Commission notice to stakeholders.
Read more online Read
  • 02 February 2021
  • 291
Assent / Informed Consent Guidance for Paediatric Clinical Trials with Medicinal Products in Europe
On 25 January 2021 the European Network of Paediatric Research at the EMA’s (Enpr-EMA’s) Working Group on Ethics developed the guidance.
Read the pdf Read
  • 02 February 2021
  • 284
FDA Updated Guidance on Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency
On 27 January 2021 the FDA updated the final guidance for industry, investigators and institutional review boards.
Read more online Read
  • 02 February 2021
  • 260
Coagulation Systems for Measurement of Viscoelastic Properties: Enforcement Policy During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency (Revised)
On 28 January 2021 the FDA published the final guidance for industry and FDA staff.
Read more online Read
  • 02 February 2021
  • 279
Overview of Comments Received on 'Draft Questions and Answers on Data Monitoring Committees Issues' (EMA/492010/2018)
On 29 January 2021 the EMA published the overview of comments on draft Q&A on Data Monitoring Committees Issues.
Read the pdf Read
  • 19 January 2021
  • 301
IND Submissions for Individualized Antisense Oligonucleotide Drug Products: Administrative and Procedural Recommendations
On 4 January 2021 the FDA announced the availability of the draft guidance for sponsor-investigators. Comments may be submitted until 4 March 2021.
Read more online Read
  • 19 January 2021
  • 285
Human Gene Therapy for Neurodegenerative Diseases
On 5 January 2021 the FDA announced the availability of the draft guidance for industry.
Read more online Read
  • 19 January 2021
  • 301
Safer Technologies Program for Medical Devices
On 6 January 2021 the FDA announced the availability of the final guidance for industry and FDA staff.
Read more online Read
  • 19 January 2021
  • 6727
Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program
On 6 January 2021 the FDA announced the availability of the final guidance for industry and FDA staff.
Read more online Read
  • 19 January 2021
  • 296
Florida Medical Doctor Pleads Guilty to Conspiring to Falsify Clinical Trial Data
On 8 January 2021 the FDA released press on a sentence of medical doctor falsifying clinical trial data.
Read more online Read
  • 19 January 2021
  • 297
COVID-19: Potency Assay Considerations for Monoclonal Antibodies and Other Therapeutic Proteins Targeting SARS-CoV-2 Infectivity
On 13 January 2021 the FDA published the guidance.
Read more online Read
  • 19 January 2021
  • 267
EMA Procedural Advice for Users of the Centralized Procedure
On 13 January 2021 the EMA updated 3 guidance on pre-/post-authorization procedural advice for users of the centralized procedure or for generic/hybrid applications.
Read more online Read
  • 19 January 2021
  • 243
EMA Updated Guidance on Obtaining and Maintaining a Scientific Opinion on a Medicine for Use Outside the EU
On 14 January 2021 the EMA updated the guidance on promoting parallel application for EU-M4all opinion and centralized marketing authorization procedure.
Read the pdf Read
  • 19 January 2021
  • 252
EMA Updated Questions & Answers on Signal Management
On 15 January 2021 the EMA published revision 4 of the Q&A on signal management.
Read the pdf Read
  • 19 January 2021
  • 244
Protecting Participants in Bioequivalence Studies for Abbreviated New Drug Applications During the COVID-19 Public Health Emergency
On 15 January 2021 the FDA published the final guidance for industry.
Read more online Read
  • 05 January 2021
  • 367
EMA Updated Guidance on Good Manufacturing Practice and Good Distribution Practice: Questions and Answers
On 16 December 2020 the EMA updated Q&A guidance on GMP and GDP in EU GMP guide part I, chapter 5.
Read more online Read
  • 05 January 2021
  • 6496
EMA Updated Questions and Answers on Labeling Flexibilities for COVID-19 Vaccines
On 16 December 2020 the EMA published the revision 1 of Q&A document on labelling flexibilities for COVID-19 vaccines.
Read the pdf Read
  • 05 January 2021
  • 415
Interacting with the FDA on Complex Innovative Trial Designs for Drugs and Biological Products
On 16 December 2020 the FDA announced the availability of the final guidance for industry.
Read more online Read
  • 05 January 2021
  • 296
ontrolled Correspondence Related to Generic Drug Development Guidance for Industry
On 16 December 2020 the FDA published the final guidance for industry.
Read more online Read
  • 05 January 2021
  • 304
Dry Eye: Developing Drugs for Treatment
On 16 December 2020 the FDA announced the availability of the draft guidance for industry. Comments may be submitted until 17 March 2021.
Read more online Read
  • 05 January 2021
  • 303
EMA Updated IRIS Guide for Applicants
On 17 December 2020 the EMA published the updated version 1.9 of IRIS guide for industry and individual applicants.
Read the pdf Read
  • 05 January 2021
  • 6470
Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion
On 17 December 2020 the FDA announced the availability of the final guidance for industry.
Read more online Read
  • 05 January 2021
  • 395
EMA Updated Clinical Trials Information System Development
On 18 December 2020 the EMA published the updated clinical trials information system (CTIS) development.
Read more online Read
  • 05 January 2021
  • 291
Procedural Advice for Post-orphan Medicinal Product Designation Activities
On 21 December 2020 the EMA published the guidance for sponsors.
Read the pdf Read
  • 05 January 2021
  • 270
Review Timelines for Applicant Responses to Complete Response Letters When a Facility Assessment Is Needed During the COVID-19 Public Health Emergency — Guidance for Industry
On 21 December 2020 the FDA announced the availability of the final guidance for industry.
Read more online Read
You can subscribe to the WSQMS Newsletter here!

Services

Quality by Design

Our extensive track record and our close collaboration with regulators positions us uniquely to support clients in QbD projects with the latest development in methodologies and regulations.

Read Download as PDF
Quality Risk Management

As recognized experts in QRM we provide leading edge knowledge and support to clients developing and implementing a QRM approach.

Read Download as PDF
Risk-based Monitoring & Study Management

With the QbD and QRM methodologies we are in a unique position to help you design your new approach to a targeted and centralized monitoring and study management approach.

Read Download as PDF
SOP Management and Re-engineering

We have developed and successfully deployed a new approach to SOP management. Structured Content Management (SCM) allows tailoring the content of an SOP to the exact needs of each user group. With this we have created a whole set of clinical development SOPs that can easily be deployed in your company.

Read Download as PDF
Quality Strategy, Quality Policy & Quality Manuals

Many years of experience with large and small organizations developing Quality Strategies and key Quality documentation such as Quality Policy and Manual tailored to the customers specific needs.

Read Download as PDF
Design & Implementation of a Quality Management System

We have worked with large and small organizations and helped them develop and deploy a fit-for-purpose QMS. Their experience has allowed them to detect early obstacles or even resistance and to propose the right change management steps.

Read Download as PDF
GCP, Quality Risk Management & Quality Methodology Training

We are proud to be able to offer you tailored training courses as an in-house training for your staff either as refresher training or for newcomers.

Read Download as PDF
Service Provider & Vendor Qualification and Assessment

We have extensive experience in qualifying vendors and designing processes ranging from pre-contract assessments (risk based) to in process audits and quality risk assessments.

Read Download as PDF
GCP Issue Management

We have combined more than 35 years of experience in the GCP field and are viewed by many of our peers in the industry as thought-leaders in compliance matters and issues.

Read Download as PDF
Independent QA Support & Services

We have a demonstrated track record of successful implementations of QA plans and strategies as well as CAPA (Corrective and Preventive Action) programs and QA infrastructure and organizations.

Read Download as PDF
Inspection Readiness Support

We have developed and implemented processes to make organizations inspection ready. A toolkit has been developed to assist teams and functions to reach an inspection ready state.

Read Download as PDF
Quality Management of Pharmacovigilance Processes

We have developed a systematic approach to ensuring a continuous oversight on safety reporting whether in clinical trials or of spontaneous cases from marketed products. This methodology is based on the QbD and QRM principle and can be tailored to the customers' need.

Read Download as PDF
Corporate Compliance

With our experience we are best positioned to define the systems’ requirements, perform a risk analysis and define and rollout of processes for health care compliance.

Read Download as PDF
Regulatory Intelligence Clinical Quality & Risk Management

Through our network, we are uniquely placed to learn early of planned changes that may impact your operations and even more important we are able to put these in the right legal and regulatory context to guide you to make the right process and organizational changes or to confidently refuse any change.

Read Download as PDF
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /